Papers on
mL-1
Electrochemically assisted sorption on oxidized multiwalled carbon nanotubes for preconcentration of Cr, Mn, Co, Ni, Cu and Zn from water samples.Sitko et al., Katowice, Poland. In Analyst, 11 Apr 2013
If measurements are performed using the EDXRF spectrometer, the detection limits are 1 ng mL-1, 5 ng mL-1, 5 ng mL-1, 7 ng mL-1, 1 ng mL-1, 8 ng mL-1 for Cr(iii), Mn(ii), Co(ii), Ni(ii), Cu(ii) and Zn(ii), respectively.
Emerging treatment for chronic migraine and refractory chronic migraine.Martelletti et al., Roma, Italy. In Expert Opin Emerg Drugs, Sep 2012
AREAS COVERED: State-of-the-art and future medical treatments of chronic migraine include: OnabotulinumtoxinA, antiepileptic drugs (Levetiracetam, Magnesium valproate hydrate, Lacosamide, BGG-492), 5-HT agonists (Lasmiditan, NXN-188, novel delivery systems of Sumatriptan, a well-established drug treatment for acute migraine), CGRP receptor antagonists (BMS-927711), ML-1 agonists (Ramelteon), orexin receptor antagonist (MK-6096), plant-derived compound (LLL-2011) and other multitarget drugs such as Tezampanel, Tonabersat, intranasal carbon dioxide and BOL-148.
Immunity to infection in IL-17-deficient mice and humans.Puel et al., New York City, United States. In Eur J Immunol, Sep 2012
In humans, the study of patients with various primary immunodeficiencies, including autosomal dominant hyper-IgE syndrome caused by dominant-negative STAT3 mutations and autosomal recessive autoimmune polyendocrinopathy syndrome type 1 caused by null mutations in AIRE, has suggested that IL-17A, IL-17F and/or IL-22 are essential for mucocutaneous immunity to Candida albicans.